• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 01 2023

QTE Development

-

February 1, 2023

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:21 am

Published: February 1, 2023

Top stories

Column – November 22, 2026

What the previous government did well and what to expect now

After three decades in the industry, I can conclude that decision-makers have a growing understanding of the strategic importance of Swedish life science. After all, this is where highly skilled jobs are created and the image of Sweden as an innovative nation is fostered, not to mention the economic surplus generated by life science exports.

Global report – November 20, 2026

Pfizer licenses in vivo CAR-T programs

Pfizer has signed an exclusive licensing deal with China-based Starna Therapeutics for three in vivo CAR-T programs targeting autoimmune diseases. Starna receives USD 330 million upfront and could earn up to USD 2.3 billion more in development and commercial milestones, plus royalties on net sales.

Business article – November 19, 2026

Evaxion refocuses on cancer vaccines

Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.

Collaboration – November 19, 2026

Gates Foundationand NordForsk partner on women’s health

The Gates Foundation and NordForsk have signed a declaration to accelerate progress in women’s health by strengthening research, evidence, and innovation that can improve the lives of women and girls.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Column - November 22, 2026

What the previous government did well and what to expect now

After three decades in the industry, I can conclude that decision-makers have a growing understanding of the strategic importance of Swedish life science. After all, this is where highly skilled jobs are created and the image of Sweden as an innovative nation is fostered, not to mention the economic surplus generated by life science exports.

Global report - November 20, 2026

Pfizer licenses in vivo CAR-T programs

Pfizer has signed an exclusive licensing deal with China-based Starna Therapeutics for three in vivo CAR-T programs targeting autoimmune diseases. Starna receives USD 330 million upfront and could earn up to USD 2.3 billion more in development and commercial milestones, plus royalties on net sales.

Business article - November 19, 2026

Evaxion refocuses on cancer vaccines

Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.

Collaboration - November 19, 2026

Gates Foundationand NordForsk partner on women’s health

The Gates Foundation and NordForsk have signed a declaration to accelerate progress in women’s health by strengthening research, evidence, and innovation that can improve the lives of women and girls.

Biotech Business - November 19, 2026

Asgard wins EUR 2.5 million EIC grant

Asgard Therapeutics has been awarded a EUR 2.5 million grant from the European Innovation Council (EIC) Accelerator to move its lead program, AT-108, toward clinical trials in 2027. The grant also makes the company eligible for up to EUR 10 million in equity investment from the EIC Fund.

Clinical Trials - November 19, 2026

First patient dosed in Cereno’s PAH trial

Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.

MedTech Business - November 19, 2026

CLS teams up with German fiber specialist

Clinical Laserthermia Systems (CLS) has signed a strategic partnership agreement with Germany’s Advanced Fiber Tools (AFT) to develop medical laser products for markets beyond its current focus on neurosurgery and urology.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.